An Immunoluminometric Assay for Cardiotrophin-1: A Newly Identified Cytokine Is Present in Normal Human Plasma and Is Increased in Heart Failure

Talwar, Suneel; Downie, Paul; Squire, Iain B.; Barnett, David; Davies, JE; Ng, Leong L.

doi:10.1006/bbrc.1999.1084

Cited by 52 publications

(58 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a multivariate model of the predictors of log wall motion index, the only signifi cant predictor was log CT-1. This demonstrates that CT-1 is elevated in heart failure in relation to the severity of LVSD 25,37 . Plasma CT-1 has high diagnostic effi cacy for heart failure (at concentration of 68 fmol/ml, sensitivity and specifi city were 95 % and 82.5 % respectively 64 ).…”

Section: Clinical Statuses and Ct-1mentioning

confidence: 69%

Cardiotrophin-1 Review

Stejskal¹,

Růžička²

2008

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Section: Clinical Statuses and Ct-1mentioning

confidence: 69%

Cardiotrophin-1 Review

Stejskal¹,

Růžička²

2008

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…These include gp130 receptor internalization and degradation and induction of intrinsic suppressor of cytokine signaling (SOCS) proteins, such as SOCS-3. 4 We and others have shown that patients with congestive heart failure have raised plasma levels of CT-1 [5][6][7] that correspond to disease severity. 6 Enhanced CT-1 secretion seems to be an early event that occurs before onset of left ventricular systolic dysfunction and therefore may have an impact on disease progression.…”

Section: See P 1430mentioning

confidence: 96%

Augmented Expression of Cardiotrophin-1 in Failing Human Hearts Is Accompanied by Diminished Glycoprotein 130 Receptor Protein Abundance

Zolk

O’Brien

et al. 2002

Circulation

View full text Add to dashboard Cite

Background-Cardiotrophin-1 (CT-1), a member of the interleukin-6 superfamily, is a potent inducer of cardiomyocyte hypertrophy that prolongs myocyte survival. Although cardiac CT-1 gene expression is known to be upregulated in some animal models of congestive heart failure, the activation state of the CT-1 system in patients with congestive heart failure is unknown. Methods and Results-This study was designed to determine left ventricular expression of CT-1 and its glycoprotein 130 (gp130)/leukemia inhibitory factor receptor complex in human end-stage heart failure due to ischemic and dilated cardiomyopathy. In addition, we investigated the activation state of signal transducer and activator of transcription 3 (STAT3), the downstream effector of gp130 signaling. In the failing left ventricular myocardium, expression levels of CT-1 mRNA and protein were significantly increased by 142% and 68%, respectively, compared with non-failing donor hearts. Immunohistochemistry confirmed the increased expression of CT-1 in cardiac myocytes. Although gp130 gene expression was increased by 91% (PϽ0.001), gp130 protein abundance was significantly diminished by 34% in the failing myocardium. In contrast, leukemia inhibitory factor receptor and suppressor of cytokine signaling-3 protein concentrations were not changed. In addition, the ratio of activated tyrosine phosphorylated STAT3 to total STAT3 was not significantly altered in failing hearts compared with non-failing controls. Conclusions-Our data suggest that gp130 receptor downregulation balances enhanced CT-1 expression in human heart failure and thereby inhibits excessive activation of the gp130 signaling pathway.

show abstract

“…However, levels of each of these cytokines are generally very low, being detected at high levels only in pathological states. For example, there is an increase in circulating CNTF in neurodegenerative disorders (18), in LIF during septic shock (19) and in CT-1 in cardiovascular disease (20). Serum IL-6 levels are also elevated with age (21) and circulating gp130 cytokines and soluble receptor isoforms are increased during inflammation (see below).…”

Section: Gp130 Actions On the Skeletonmentioning

confidence: 99%

GP130 cytokines and bone remodelling in health and disease

Sims¹,

Walsh²

2010

BMB Reports

107

View full text Add to dashboard Cite

Gp130 cytokinesGlycoprotein 130 (gp130) is a receptor subunit capable of intracellular signalling that is required for the cellular action of a wide range of cytokines. The most well known of these are interleukin (IL-) 6 and IL-11, leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), oncostatin M (OSM) and ciliary neurotrophic factor (CNTF). Every cytokine that binds to gp130 generates specific intracellular signalling events by forming specific receptor:ligand complexes, each with distinct components and/or architecture (Fig.

show abstract

An Immunoluminometric Assay for Cardiotrophin-1: A Newly Identified Cytokine Is Present in Normal Human Plasma and Is Increased in Heart Failure

Cited by 52 publications

References 14 publications

Cardiotrophin-1 Review

Cardiotrophin-1 Review

Augmented Expression of Cardiotrophin-1 in Failing Human Hearts Is Accompanied by Diminished Glycoprotein 130 Receptor Protein Abundance

GP130 cytokines and bone remodelling in health and disease

Contact Info

Product

Resources

About